Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer : CheckMate 153
PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab.
METHODS: Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration).
RESULTS: Of 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post-random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]). Median overall survival from random assignment was longer with continuous versus 1-year fixed-duration treatment in the PFS (not reached v 32.5 months; HR, 0.61 [95% CI, 0.37 to 0.99]) and ITT (not reached v 28.8 months; HR, 0.62 [95% CI, 0.42 to 0.92]) populations. Few new-onset treatment-related adverse events occurred. No new safety signals were identified.
CONCLUSION: To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.
| Errataetall: |
CommentIn: J Clin Oncol. 2020 Nov 20;38(33):3830-3832. - PMID 32997574 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 38(2020), 33 vom: 20. Nov., Seite 3863-3873 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Waterhouse, David M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 25.03.2021 Date Revised 21.11.2021 published: Print-Electronic CommentIn: J Clin Oncol. 2020 Nov 20;38(33):3830-3832. - PMID 32997574 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.20.00131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314829229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314829229 | ||
| 003 | DE-627 | ||
| 005 | 20231225153600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.20.00131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314829229 | ||
| 035 | |a (NLM)32910710 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Waterhouse, David M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer |b CheckMate 153 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2021 | ||
| 500 | |a Date Revised 21.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Clin Oncol. 2020 Nov 20;38(33):3830-3832. - PMID 32997574 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab | ||
| 520 | |a METHODS: Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks). Those still receiving treatment at 1 year, including patients perceived to be deriving benefit despite radiographic progression, were randomly assigned to continue nivolumab until disease progression or unacceptable toxicity or to stop nivolumab with the option of on-study retreatment after disease progression (1-year fixed duration) | ||
| 520 | |a RESULTS: Of 1,428 patients treated, 252 were randomly assigned to continuous (n = 127) or 1-year fixed-duration (n = 125) treatment (intent-to-treat [ITT] population). Of these, 89 and 85 patients in the continuous and 1-year fixed-duration arms, respectively, had not progressed (progression-free survival [PFS] population). With minimum post-random assignment follow-up of 13.5 months, median PFS was longer with continuous versus 1-year fixed-duration treatment (PFS population: 24.7 months v 9.4 months; hazard ratio [HR], 0.56 [95% CI, 0.37 to 0.84]). Median overall survival from random assignment was longer with continuous versus 1-year fixed-duration treatment in the PFS (not reached v 32.5 months; HR, 0.61 [95% CI, 0.37 to 0.99]) and ITT (not reached v 28.8 months; HR, 0.62 [95% CI, 0.42 to 0.92]) populations. Few new-onset treatment-related adverse events occurred. No new safety signals were identified | ||
| 520 | |a CONCLUSION: To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Garon, Edward B |e verfasserin |4 aut | |
| 700 | 1 | |a Chandler, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a McCleod, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hussein, Maen |e verfasserin |4 aut | |
| 700 | 1 | |a Jotte, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Horn, Leora |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel, Davey B |e verfasserin |4 aut | |
| 700 | 1 | |a Keogh, George |e verfasserin |4 aut | |
| 700 | 1 | |a Creelan, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Einhorn, Lawrence H |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Kasbari, Samer |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolinakos, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Babu, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Couture, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Leighl, Natasha B |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenschein, George |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Gunuganti, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ang |e verfasserin |4 aut | |
| 700 | 1 | |a Aanur, Nivedita |e verfasserin |4 aut | |
| 700 | 1 | |a Spigel, David R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 38(2020), 33 vom: 20. Nov., Seite 3863-3873 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:33 |g day:20 |g month:11 |g pages:3863-3873 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.20.00131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 33 |b 20 |c 11 |h 3863-3873 | ||